[{"id":"f29dab42-3218-4cee-9ccf-b710607d907c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669067","created_at":"2021-01-19T20:44:14.797Z","updated_at":"2024-07-02T16:35:55.237Z","phase":"Phase 1b/2","brief_title":"TL-895 and KRT-232 Study in Acute Myeloid Leukemia","source_id_and_acronym":"NCT04669067","lead_sponsor":"Telios Pharma, Inc.","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • TP53 wild-type","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232) • TL895"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-02-17"}]